NCT00891007View on ClinicalTrials.gov

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

August 31, 2010

Conditions
Measles
Interventions
BIOLOGICAL

MVA-mBN85B

Low Dose arm, 1x 10E7 TCID50

BIOLOGICAL

MVA-mBN85B

Normal Dose arm, 1x 10E8 TCID50

BIOLOGICAL

Rouvax

Standard measles vaccine, approved in South Africa

Trial Locations (1)

2013

Chris Hani Baragwanath Hospital, Respiratory and Meningeal Pathogens Research Unit, Bertsham

Sponsors

Lead Sponsor

Bavarian Nordic
All Listed Sponsors
lead

Bavarian Nordic

INDUSTRY

NCT00891007 - Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years | Biotech Hunter | Biotech Hunter